Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lancing Device Comparison Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01740778
Recruitment Status : Completed
First Posted : December 4, 2012
Last Update Posted : December 4, 2012
Sponsor:
Information provided by (Responsible Party):
Mary Kate Pynes, Facet Technologies

Brief Summary:
To evaluate pain responses using the Aurora lancing device and Velvet 33g lancet compared to other common, commercially available lancing systems. Subjects will test the devices at a depth setting sufficient to provide enough blood volume to trigger the OneTouch® Ultra®Mini blood glucose meter using OneTouch® Ultra® blood glucose test strips from either the fingertip or alternate site testing.

Condition or disease
Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Detailed Description:

A low-pain lancing is being developed code name Aurora) for use with a 33g proprietary lancet (code name Velvet). This study evaluates the pain associated with finger lancing using this device and compares that pain to other commercially available lancing devices and associated lancets.

All lancets used in the study are currently commercially available except the Facet 33g lancet, which is a prototype version of commercially available lancets.

The Roche Multiclix, Roche Softclix, One Touch Comfort and Bayer Microlet 2 lancing devices are all commercially available.

The Aurora Lancing Device is effective in obtaining a sufficient blood sample for performing an accurate blood glucose measurement; and the benefits of using the Aurora Lancing Device outweighs any residual risks associated with the product. Literature concerning blood glucose testing was researched by using popular medical databases such as pubmed.gov, diabeteshealth.com, clinicaltrial.gov and search terms lancing device, clinical study, blood volume and pain. Using other popular search engines such as Google was beneficial in helping to support claims concerning safety and efficacy. A commercial database company, NERAC was used as a part of the literature research effort. Our review, together with preliminary in-house bench testing, shows that the Aurora Lancing Device should be able to:

  • Obtain enough blood volume for a meter reading that measures blood glucose levels;
  • Is as safe as comparative lancing devices currently on the market;
  • Produces no more pain than comparative lancing devices currently on the market using a 28 gauge needle; and
  • Is representative of "current state of the art" The Aurora Lancing Device uses a 33 gauge, uniquely designed lancet developed under project Velvet. The blood lancet is designed so that it can only be used in the Aurora lancing device. The lancing device features multiple depth settings and includes alternate site test capability. The lancet guidance system is designed to maximize lancet control thereby increasing comfort and reducing pain perception. The Aurora lancing device is comparable to the Roche Softclix and other lancing devices already in commercial distribution. Like Aurora the Roche Softclix lancing device offers diabetics a unique lancet design and precise lancet motion. Roche Softclix uses a 28 gauge lancet and has eleven depth settings as well as alternative site test capability.

Layout table for study information
Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Lancing Device Comparison Study
Study Start Date : August 2009
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine


Group/Cohort
Study Group 1
Aurora vs. Microlet 2
Study Group 2
Aurora vs. SoftClix
Study Group 3
Aurora vs. One Touch Comfort
Study Group 4
Aurora vs. Multiclix



Primary Outcome Measures :
  1. Blood Glucose Reading [ Time Frame: 1-1 hour visit during the study ]

    During the first part of the study, subjects will test their lancing devices at a depth setting sufficient to provide enough blood volume to trigger the OneTouch® Ultra®Mini blood glucose meter using OneTouch® Ultra® blood glucose test strips.

    The second part of the study will generate the pain data associated with the Alternate site testing (AST) will also be performed on the palm of the hand and the forearm with the Aurora device and Velvet 33g lancet.

    Each lancing event, in the first portion of the study, is considered successful if at least 2 out of 3 lancing events are successful in producing enough blood to trigger the One Touch® Ultra®Mini blood glucose meter.



Secondary Outcome Measures :
  1. Pain Scale Rating [ Time Frame: 1- 1 hour visit during the study ]

    The second part of the study will generate the pain data associated with the Aurora device and Velvet 33g lancet along with the study comparative device. During the second visit, alternate site testing (AST) will also be performed on the palm of the hand and the forearm with the Aurora device and Velvet 33g lancet.

    The second portion of the study will compare and report the differences in pain between the device/lancet combinations. Pain will be assessed for each successful fingerstick per the visual analog scale (VAS).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Gender: Approximately 50% male, 50% female; Type Diabetes: 25% Type 1, 75% Type 2 Age: 18 or older
Criteria

Inclusion Criteria:

Must have been diagnosed with type 1 or type 2 diabetes for at least 1 year Must be doing SMBG, at least twice daily for at least 6 months Must be 18 years of age and older Must have healthy fingers and hands Must be able to read instructions in English. Must be able to perform all tasks in the protocol.

Exclusion Criteria:

Subjects with neuropathy or any other nerve damage in the hand or fingers (this will be discovered through the monofilament test)

Subjects who are taking prescription anti-coagulants or more than one full aspirin per day during the past week or have clotting problems that may prolong bleeding (persons taking Plavix or a daily low dose aspirin will not be excluded but this will be recorded).

Subjects taking prescription medications for neuropathy.

Subjects with hemophilia or any other bleeding disorder.

subjects with infection with a blood borne pathogen (e.g., HIV, hepatitis).

Subjects having a condition such as a cognitive disorder, which in the opinion of the Investigator would put the person at risk or seriously compromise the integrity of the study (PI will sign CRF if subject is excluded).

Subjects with missing digits.

Subjects who are pregnant or nursing.

Subjects on chemotherapy.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01740778


Sponsors and Collaborators
Facet Technologies
Investigators
Layout table for investigator information
Principal Investigator: Ashley Shemain, MBA SHEMAIN CONSULTING GROUP, LLC
Layout table for additonal information
Responsible Party: Mary Kate Pynes, CRA, Facet Technologies
ClinicalTrials.gov Identifier: NCT01740778    
Other Study ID Numbers: FT-2009-Aurora
First Posted: December 4, 2012    Key Record Dates
Last Update Posted: December 4, 2012
Last Verified: November 2012
Keywords provided by Mary Kate Pynes, Facet Technologies:
Diabetes
Medical Device
Lancing
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases